MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Inicio・Lista de Acciones・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Cerrado

1.52 3.4

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

1.46

Máximo

1.54

Métricas clave
By Trading Economics
Ingresos	13M -43M
Margen de beneficios	-2,190.837
Empleados	171
EBITDA	17M -42M

Recomendaciones
By TipRanks
Recomendaciones	Neutral
Estimación a 12 Meses	+79.87% upside

Dividendos
By Dow Jones
Próximas Ganancias	6 nov 2025

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-13M 91M
Apertura anterior	-1.88
Cierre anterior	1.52

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

1.43 / 1.6 Soporte y Resistencia

Pliant Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

8 oct 2025, 20:45 UTC

Ganancias

Costco Wholesale Sales Climb in September, Early October

8 oct 2025, 20:12 UTC

Principales Movimientos del Mercado

Adquisiciones, fusiones, absorciones

TaskUs Shares Fall After Holders Reject Take-Private Deal

8 oct 2025, 16:39 UTC

Principales Movimientos del Mercado

Mining Shares Rise as Gold Prices Soar

8 oct 2025, 23:45 UTC

Charlas de Mercado

Nikkei May Rise on Weaker Yen -- Market Talk

8 oct 2025, 23:43 UTC

Charlas de Mercado

Gold Falls on Possible Profit-Taking -- Market Talk

8 oct 2025, 23:18 UTC

Adquisiciones, fusiones, absorciones

JD Logistics to Finance Acquisition Using Internal Funds

8 oct 2025, 23:17 UTC

Adquisiciones, fusiones, absorciones

JD Logistics to Buy On-Demand Delivery Services Business for US$270.0M

8 oct 2025, 23:16 UTC

Adquisiciones, fusiones, absorciones

JD Logistics to Buy JD.com's On-Demand Delivery Services Business Dajiang and Dasheng

8 oct 2025, 21:54 UTC

Charlas de Mercado

Ganancias

James Hardie Could Beat Annual Earnings Goal -- Market Talk

8 oct 2025, 21:30 UTC

Charlas de Mercado

Boab Metals Bull Delivers Second Upgrade in a Month -- Market Talk

8 oct 2025, 21:26 UTC

Charlas de Mercado

Ganancias

Transurban's 1Q Traffic Growth Beats Hopes -- Market Talk

8 oct 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

8 oct 2025, 19:15 UTC

Charlas de Mercado

Geopolitical Risk Supports Gains in Oil Futures -- Market Talk

8 oct 2025, 19:01 UTC

Charlas de Mercado

U.S. Natural Gas Futures Pull Back Ahead of Storage Data -- Market Talk

8 oct 2025, 18:47 UTC

Charlas de Mercado

Coca-Cola North America Sales Buoy International Weakness -- Market Talk

8 oct 2025, 18:46 UTC

Adquisiciones, fusiones, absorciones

TaskUs: Neither Party Will Be Required to Pay Termination Fee as Result of Planned Mutual Decision to Terminate

8 oct 2025, 18:46 UTC

Adquisiciones, fusiones, absorciones

TaskUs Will Remain a Publicly Traded Co >TASK

8 oct 2025, 18:46 UTC

Adquisiciones, fusiones, absorciones

TaskUs Does Not Plan to Convene Another Special Meeting of Stockholders >TASK

8 oct 2025, 18:45 UTC

Adquisiciones, fusiones, absorciones

TaskUs Didn't Receive Votes Necessary to Approve Transaction Agreement With Affil of Blackstone >TASK

8 oct 2025, 18:07 UTC

Charlas de Mercado

Mexico's Inflation Seen Edging Up in September -- Market Talk

8 oct 2025, 16:20 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Energy & Utilities Roundup: Market Talk

8 oct 2025, 16:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

8 oct 2025, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

8 oct 2025, 15:57 UTC

Charlas de Mercado

Oil Rises Despite U.S. Crude Stockpiles Build -- Market Talk

8 oct 2025, 15:56 UTC

Charlas de Mercado

Teck Resources' Chile Mine Issues Appear Transitory -- Market Talk

8 oct 2025, 15:53 UTC

Charlas de Mercado

Argentine Sovereign Debt Seen as Attractive -- Market Talk

8 oct 2025, 15:44 UTC

Adquisiciones, fusiones, absorciones

Staar Surgical: Broadwood's Proposal to Vote Down Merger Could Allow It to Take Control Without Paying Any Premium

8 oct 2025, 15:44 UTC

Adquisiciones, fusiones, absorciones

Staar Surgical Board and Management Disagree With Recommendation Issued by Glass Lewis >STAA

8 oct 2025, 15:43 UTC

Adquisiciones, fusiones, absorciones

STAAR Surgical Board Reiterates Unanimous Recommendation Holders Vote for Alcon Merger

8 oct 2025, 15:42 UTC

Adquisiciones, fusiones, absorciones

Oracle Is a Buy-the-Dip Opportunity, Analyst Says. How the Stock Could Rise 23%. -- Barrons.com

Comparación entre iguales

Cambio de precio

Pliant Therapeutics Inc previsión

Precio Objetivo

By TipRanks

79.87% repunte

Estimación a 12 Meses

Media 2.68 USD 79.87%

Máximo 4 USD

Mínimo 1.7 USD

De acuerdo con 6 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Pliant Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

6 ratings

Comprar

Mantener

Vender

De acuerdo con 6 analistas que ofrecen calificaciones bursátiles a para Pliant Therapeutics Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

1.43 / 1.6Soporte y Resistencia

Recent bearish events outweigh bullish events.

There is one bearish event.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.